These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 33112687)
1. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Chevallier P; Berceanu A; Peterlin P; Garnier A; Le Bourgeois A; Imbert BM; Daguindau E; Mahé B; Dubruille V; Blin N; Touzeau C; Gastinne T; Lok A; Tessoulin B; Vantyghem S; Desbrosses Y; Bressollette C; Duquesne A; Eveillard M; Le Bris Y; Dormoy A; Malugani C; Deconinck E; Moreau P; Le Gouill S; Béné MC; Guillaume T Acta Oncol; 2021 Apr; 60(4):466-474. PubMed ID: 33112687 [TBL] [Abstract][Full Text] [Related]
2. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome. Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418 [TBL] [Abstract][Full Text] [Related]
3. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903 [TBL] [Abstract][Full Text] [Related]
4. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504 [TBL] [Abstract][Full Text] [Related]
5. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. Sanz J; Galimard JE; Labopin M; Afanasyev B; Angelucci E; Ciceri F; Blaise D; Cornelissen JJ; Meijer E; Diez-Martin JL; Koc Y; Rovira M; Castagna L; Savani B; Ruggeri A; Nagler A; Mohty M; J Hematol Oncol; 2020 May; 13(1):46. PubMed ID: 32375860 [TBL] [Abstract][Full Text] [Related]
6. Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia. Barkhordar M; Kasaeian A; Janbabai G; Kamranzadeh Fumani H; Tavakoli S; Rashidi AA; Mousavi SA; Ghavamzadeh A; Vaezi M Front Immunol; 2022; 13():921293. PubMed ID: 35990618 [TBL] [Abstract][Full Text] [Related]
7. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial. Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642 [TBL] [Abstract][Full Text] [Related]
8. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980 [TBL] [Abstract][Full Text] [Related]
9. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. Wang Y; Wu DP; Liu QF; Xu LP; Liu KY; Zhang XH; Yu WJ; Xu Y; Huang F; Huang XJ J Hematol Oncol; 2019 Sep; 12(1):88. PubMed ID: 31481121 [TBL] [Abstract][Full Text] [Related]
10. Effect of Graft-versus-Host Disease on Post-Transplantation Outcomes following Single Cord Blood Transplantation Compared with Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Adult Acute Myeloid Leukemia. Konuma T; Matsuda K; Shimomura Y; Tanoue S; Sugita J; Inamoto Y; Hirayama M; Ara T; Nakamae H; Ota S; Maruyama Y; Eto T; Uchida N; Tanaka M; Ishiwata K; Koi S; Takahashi S; Ozawa Y; Onizuka M; Kanda Y; Kimura T; Ichinohe T; Atsuta Y; Kanda J; Yanada M Transplant Cell Ther; 2023 Jun; 29(6):365.e1-365.e11. PubMed ID: 36889507 [TBL] [Abstract][Full Text] [Related]
11. Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts. Arcuri LJ; Hamerschlak N; Rocha V; Bonfim C; Kerbauy MN Transplant Cell Ther; 2021 Sep; 27(9):782.e1-782.e7. PubMed ID: 34146733 [TBL] [Abstract][Full Text] [Related]
12. Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation. Wada F; Kanda J; Kamijo K; Nishikubo M; Yoshioka S; Ishikawa T; Ueda Y; Akasaka T; Arai Y; Izumi K; Hirata H; Ikeda T; Yonezawa A; Anzai N; Watanabe M; Imada K; Yago K; Tamura N; Itoh M; Masuo Y; Kunitomi A; Takeoka T; Kitano T; Arima N; Hishizawa M; Asagoe K; Kondo T; Takaori-Kondo A Cell Transplant; 2023; 32():9636897231194497. PubMed ID: 37646153 [TBL] [Abstract][Full Text] [Related]
13. Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant. Bourgeois AL; Jullien M; Garnier A; Peterlin P; Béné MC; Guillaume T; Chevallier P Clin Transl Med; 2023 Apr; 13(4):e1242. PubMed ID: 37140099 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. Nagler A; Labopin M; Dholaria B; Angelucci E; Afanasyev B; Cornelissen JJ; Sica S; Meijer E; Ciceri F; Van Gorkom G; Kröger N; Martin H; Pioltelli P; Risitano A; Canaani J; Savani BN; Sanz J; Mohty M Clin Cancer Res; 2021 Feb; 27(3):843-851. PubMed ID: 33148668 [TBL] [Abstract][Full Text] [Related]
15. Post-Transplant Cyclophosphamide and Thymoglobulin, a Graft-Versus-Host Disease Prophylaxis in Matched Sibling Donor Peripheral Blood Stem Cell Transplantations. Kunacheewa C; Owattanapanish W; Jirabanditsakul C; Issaragrisil S Cell Transplant; 2020; 29():963689720965900. PubMed ID: 33035116 [TBL] [Abstract][Full Text] [Related]
16. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295 [TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Im A; Rashidi A; Wang T; Hemmer M; MacMillan ML; Pidala J; Jagasia M; Pavletic S; Majhail NS; Weisdorf D; Abdel-Azim H; Agrawal V; Al-Homsi AS; Aljurf M; Askar M; Auletta JJ; Bashey A; Beitinjaneh A; Bhatt VR; Byrne M; Cahn JY; Cairo M; Castillo P; Cerny J; Chhabra S; Choe H; Ciurea S; Daly A; Perez MAD; Farhadfar N; Gadalla SM; Gale R; Ganguly S; Gergis U; Hanna R; Hematti P; Herzig R; Hildebrandt GC; Lad DP; Lee C; Lehmann L; Lekakis L; Kamble RT; Kharfan-Dabaja MA; Khandelwal P; Martino R; Murthy HS; Nishihori T; O'Brien TA; Olsson RF; Patel SS; Perales MA; Prestidge T; Qayed M; Romee R; Schoemans H; Seo S; Sharma A; Solh M; Strair R; Teshima T; Urbano-Ispizua A; Van der Poel M; Vij R; Wagner JL; William B; Wirk B; Yared JA; Spellman SR; Arora M; Hamilton BK Biol Blood Marrow Transplant; 2020 Aug; 26(8):1459-1468. PubMed ID: 32434056 [TBL] [Abstract][Full Text] [Related]
18. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Battipaglia G; Labopin M; Hamladji RM; Blaise D; Chevallier P; Brissot E; Gerbitz A; Socié G; Afanasyev B; Ciceri F; Meijer E; Koc Y; Cornelissen JJ; Huynh A; Ozdogu H; Maertens J; Paul F; Labussière-Wallet H; Ruggeri A; Aljurf M; Bazarbachi A; Savani B; Nagler A; Mohty M Cancer; 2021 Jan; 127(2):209-218. PubMed ID: 33119152 [TBL] [Abstract][Full Text] [Related]
19. Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Battipaglia G; Labopin M; Blaise D; Diez-Martin JL; Bazarbachi A; Vitek A; Chevallier P; Castagna L; Grillo G; Daguindau E; López-Jiménez J; Koc Y; Ruggeri A; Nagler A; Mohty M Transplant Cell Ther; 2022 Sep; 28(9):587.e1-587.e7. PubMed ID: 35714906 [TBL] [Abstract][Full Text] [Related]
20. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]